These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37890053)

  • 21. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
    Mozersky J; Sankar P; Harkins K; Hachey S; Karlawish J
    JAMA Neurol; 2018 Jan; 75(1):44-50. PubMed ID: 29059270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
    Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
    Lim YY; Maruff P; Getter C; Snyder PJ
    Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure: A Systematic Review.
    Couch E; Ashford MT; Zhang W; Prina M
    Alzheimer Dis Assoc Disord; 2023 Jul-Sep 01; 37(3):246-258. PubMed ID: 37561950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
    JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
    Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
    JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
    Cousins O; Schubert JJ; Chandra A; Veronese M; Valkimadi P; Creese B; Khan Z; Arathimos R; Hampshire A; Rosenzweig I; Ballard C; Corbett A; Aasland D; Velayudhan L; O'Neill M; Collier D; Awais R; Sander K; Årstad E; Howes O; Turkheimer F; Hodges A
    J Neuroinflammation; 2023 Nov; 20(1):272. PubMed ID: 37990275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
    Bucci M; Chiotis K; Nordberg A;
    Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
    Deters KD; Napolioni V; Sperling RA; Greicius MD; Mayeux R; Hohman T; Mormino EC
    Neurology; 2021 Mar; 96(11):e1491-e1500. PubMed ID: 33568538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
    Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
    Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
    Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
    Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.
    Smith HS; Robinson JO; Levchenko A; Pereira S; Pascual B; Bradbury K; Arbones V; Fong J; Shulman JM; McGuire AL; Masdeu J
    J Alzheimers Dis; 2024; 97(3):1261-1274. PubMed ID: 38250770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "I know that my role is going to change": a mixed-methods study of the relationship between amyloid-β PET scan results and caregiver burden.
    Couch E; Belanger E; Gadbois EA; DePasquale N; Zhang W; Wetle T
    Aging Clin Exp Res; 2023 Feb; 35(2):387-397. PubMed ID: 36484946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
    Li J; Zheng C; Ge Q; Yan S; Paranjpe MD; Hu S; Zhou Y;
    J Neurosci Res; 2022 Feb; 100(2):670-680. PubMed ID: 34882830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
    Yoon SH; Kim HK; Lee JH; Chun JH; Sohn YH; Lee PH; Ryu YH; Cho H; Yoo HS; Lyoo CH
    Neurology; 2023 Nov; 101(21):e2162-e2171. PubMed ID: 37813585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.